Skip to main content
MSLE logo

Satellos Bioscience Inc. (MSLE) Stock: Price, Forecast & Analyst Target

Satellos Bioscience Inc. (MSLE) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $5.80 (-2.36%), as of the Nov 19, 2026 trading session; market cap $123M.

Educational signal · not a buy or sell recommendation · How to read this

$5.80 −$0.14 (-2.36%) Market Cap $123M

Satellos Bioscience Inc. · MSLE · NASDAQ

Satellos Bioscience Inc. is a Toronto-based regenerative medicine company focused on developing innovative therapeutics for muscle diseases. Utilizing its proprietary MyoReGenX™ technology platform, the company aims to address stem cell regeneration deficits.

Price as of Nov 19, 2026

Key Statistics

32 of 100

MoonshotScore v2 · Satellos Bioscience (MSLE)

Weak
Business Quality Thin (30)
Financial Safety Okay (55)
Valuation Rich (34)
Growth Durability Shrinking (6)
Momentum Quiet (44)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, stalling growth and an expensive valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Okay; Valuation: Rich; Growth Durability: Shrinking; Momentum: Quiet.

  • EPS beat 0 of the last 4 reports
  • Altman Z -3.25 · Piotroski F 1
  • ROE -70.4% · ROA -41.9% · current ratio 11.22

Holding back: weak fundamentals, a rich price, soft growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for MSLE (52 recorded, newest six shown)
RecordedScoreBand
33Weak
33Weak
32Weak
32Weak
32Weak
32Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$5.80
Change on the day-2.36%
Market capitalisation$123M—
Shares traded on the day75.5K

Price & events

Other perspectives

Council score for Satellos Bioscience (MSLE): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Weak
Financial Safety Neutral
Valuation Weak
Growth Durability Negative
Momentum Neutral

Legends Council

3 lenses, 3 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
ROE Negative
Gross Margin Negative

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Satellos Bioscience (MSLE), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Satellos Bioscience Inc. (MSLE) is listed on NASDAQ. It employs 18 people. The market values it at $123M.

2 · Latest results

What do the latest results show for Satellos Bioscience (MSLE)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for Satellos Bioscience (MSLE)?

Short answer

What is holding it back is weak fundamentals, a rich price, soft growth. The distress and quality screens read Altman Z -3.25 · Piotroski F 1. Trailing ratios: ROE -70.4% · ROA -41.9% · current ratio 11.22.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -3.25 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-70.4%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 1 of the last 4 reported quarters.
4 · What to check next?

What should you watch next at Satellos Bioscience (MSLE)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $0.00 · EPS -2.19 · 0 analysts. Current published price targets run low $18.00 · high $24.00 · consensus $20.00 · median $18.00 against a quoted price of $5.80 (as of Nov 19, 2026).

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • No quarterly income statement is held for MSLE.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Satellos Bioscience compare with its peers?

Short answer

Satellos Bioscience's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.07 Nov 19, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Named competitor$58.34 Nov 19, 2026$119B85 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Named competitor$443.89 Nov 18, 2026$240B84 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.28 Nov 19, 2026$546M68 5-pillar Nov 18, 2026
Satellos Bioscience (MSLE) — this page$5.80$123M32

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$18.00 – $24.00
Consensus target
$20.00
Median target
$18.00
Revenue estimate
$0.00
EPS estimate
$-2.19

Consensus record · Captured .

Measured against a quoted price of $5.80 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MSLE in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported MSLE in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Satellos Bioscience (MSLE)?

Read these with our analysis →

Satellos Bioscience Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the MSLE research dossier (written Mar 16, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for MSLE?

MSLE carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Satellos Bioscience Inc. is a Toronto-based regenerative medicine company focused on developing innovative therapeutics for muscle diseases.

Is MSLE a good stock to buy?

Stock Expert AI does not rate MSLE buy, sell or hold. Satellos Bioscience Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the MSLE stock price today?

The last price recorded for Satellos Bioscience Inc. (MSLE), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the MSLE price target?

The analyst consensus price target for Satellos Bioscience Inc. (MSLE), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What is Satellos Bioscience Inc. Common Stock's drug pipeline status?

Satellos Bioscience Inc. is currently in the early stages of developing its drug pipeline, with a focus on therapeutics for muscle diseases.

What are the key factors to evaluate for MSLE?

Satellos Bioscience Inc. (MSLE) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Headquartered in Toronto, Canada, providing access to a robust healthcare ecosystem. Not financial advice.

How frequently does MSLE data refresh on this page?

MSLE's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven MSLE's recent stock price performance?

Satellos Bioscience Inc. (MSLE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative proprietary technology platform (MyoReGenX™). See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MSLE overvalued or undervalued right now?

Satellos Bioscience Inc. (MSLE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.